Vigabatrin Relapse Risk After Response in Infantile Spasms

What was studied

Researchers reviewed records from 164 infants with infantile epileptic spasms syndrome who achieved an electroclinical response within 30 days of starting vigabatrin, either alone or with hormonal treatment, and remained in remission for at least 30 days.

They examined whether dose, treatment duration, developmental status, other seizure types, prior relapse, and combined treatment were associated with later relapse.

What they found

Sixty-three infants (38%) experienced a relapse of epileptic spasms. The median time from initial response to relapse was 7.5 months. Among those who relapsed, 21 did so after stopping vigabatrin.

Relapse risk was higher among infants who had relapsed before, had other seizure types when spasms began, or had abnormal development at diagnosis. A moderate vigabatrin dose of 100–149 mg/kg/day was associated with a lower relapse risk than lower doses. An analysis with limited statistical power did not find a significant association between ongoing vigabatrin treatment and time to relapse.

Limits of the evidence

This was a retrospective observational study, so it identifies associations but cannot establish that a particular vigabatrin dose or treatment duration caused a lower relapse risk. It included only infants who initially responded and remained in remission for at least 30 days, so the findings may not apply to all infants with this condition. Although the researchers adjusted for some factors that could affect treatment duration, unmeasured differences may remain. The analysis of ongoing vigabatrin exposure was underpowered, and the study did not establish the ideal treatment duration.

For families and caregivers

Relapse after an initial response was common in this group. Prior relapse, other seizure types at onset, and abnormal development at diagnosis may help care teams identify infants who need especially close follow-up. Moderate-dose vigabatrin was associated with lower relapse risk than lower doses, but the study does not show that changing or extending treatment will prevent relapse. Treatment decisions should be individualized with the treating clinician.

What to watch next

Prospective studies are needed to confirm these findings and clarify how vigabatrin dose and treatment duration might be individualized to reduce relapse risk.

Terms in this summary

Infantile epileptic spasms syndrome (IESS)

A serious seizure disorder beginning in infancy that causes epileptic spasms and is associated with characteristic EEG abnormalities.

Vigabatrin

An antiseizure medicine used to treat infantile epileptic spasms syndrome.

Electroclinical response

A response involving both the clinical seizures and associated electrical brain activity measured by EEG.

Relapse

The return of epileptic spasms after a period of remission.

Retrospective cohort study

A study that looks back at existing medical records for a defined group of patients.

Hazard ratio (HR)

A measure comparing how quickly an event occurs between groups. Values above 1 indicate a higher event rate, while values below 1 indicate a lower event rate.

Confidence interval (CI)

A range showing the uncertainty around an estimate; wider ranges generally indicate less precision.

Hormonal therapy

Treatment with hormones such as ACTH or prednisolone, which may be used for infantile spasms.